Skip to main content

Table 2 The pooled results and evidence quality in efficacy outcomes

From: Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies

Outcome RCT NRCT Cohort study
Estimate (95% CI) Evidence quality a Estimate (95% CI) Evidence quality a Estimate (95% CI) Evidence quality a
Short-term outcome
 ORR RR 1.34 (0.91–1.98) Moderate RR 1.14 (0.85–1.53) Low RR 1.39 (0.81–2.39) Very low
 DCR RR 1.11 (0.94–1.30) Moderate RR 1.09 (0.91–1.30) Low RR 1.07 (0.94–1.21) Very low
Survival outcome
 OS HR 0.68 (0.42–0.94) * Very low
 PFS HR 0.71 (0.51–0.90) * Very low
  1. a The evidence quality was evaluated by GRADE. Moderate: we are moderately confident in the effect estimate (the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different); Low: our confidence in the effect estimate is limited (the true effect may be substantially different from the estimate of the effect); Very low: we have very little confidence in the effect estimate (the true effect is likely to be substantially different from the estimate of effect)
  2. * A statistically significant difference exists (P < 0.05)